Rina Hui Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. — Best of the Best Orals - Clinical Research
• Clinical activity, patient-reported outcomes, and safety with durvalumab after chemoradiation in locally advanced, unresectable NSCLC: PACIFIC study — Poster Session 1